Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. | Zendy

David D. Waters | Zendy; Lyall Higginson | Zendy; Peter Gladstone | Zendy; B P Kimball | Zendy; M. Le May | Zendy; Stephen J. Boccuzzi | Zendy; Jacques Lespérance | Zendy

Open Access

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

Author(s) -

David D. Waters,

Lyall Higginson,

Peter Gladstone,

B P Kimball,

M. Le May,

Stephen J. Boccuzzi,

Jacques Lespérance

Publication year - 1994

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.89.3.959

Subject(s) - lovastatin , medicine , placebo , coronary atherosclerosis , hyperlipidemia , reductase , cholesterol , cardiology , hmg coa reductase , lipoprotein , gastroenterology , urology , endocrinology , coronary artery disease , pathology , diabetes mellitus , enzyme , biochemistry , chemistry , alternative medicine

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors are widely prescribed for hyperlipidemia, yet their effect on the evolution of coronary atherosclerosis has not been defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research